Loading...

Home
ETF
MLTX

MLTX

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

MLTX News

CFO Sells 39,120 Shares of MoonLake Immunotherapeutics

MoonLake CFO Sells Shares Amid Market Volatility

4d agoNASDAQ.COM

MoonLake Immunotherapeutics Shares Drop Amid Secondary Offering

Jun 25 2026Fool

MoonLake Aims to Raise $200 Million to Support Drug Development

Jun 25 2026NASDAQ.COM

MoonLake Immunotherapeutics Upsizes Offering to $200 Million Amid Strong Phase 3 Data

Jun 24 2026stocktwits

MoonLake Immunotherapeutics Prices $200M Public Offering

Jun 24 2026seekingalpha

MoonLake Immunotherapeutics Prices $200 Million Upsized Public Offering

Jun 24 2026NASDAQ.COM

MoonLake Immunotherapeutics Prices Public Offering at $20 per Share

Jun 24 2026Newsfilter

MoonLake Immunotherapeutics Raises $150 Million in Public Offering

Jun 23 2026NASDAQ.COM

MoonLake Immunotherapeutics Proposes $150M Public Offering

Jun 22 2026seekingalpha

MoonLake Immunotherapeutics Shares Surge 15% on Positive Trial Results

Jun 22 2026stocktwits

Middle East Tensions Ease Amid New China Trade Restrictions

Jun 22 2026stocktwits

MoonLake Immunotherapeutics Reports Positive Phase 3 Trial Results for Sonelokimab

Jun 22 2026NASDAQ.COM

US-Iran Negotiations and Market Reactions

Jun 22 2026stocktwits

MoonLake Reports Strong Phase 3 Results for Sonelokimab Treatment

Jun 22 2026stocktwits

MoonLake's Sonelokimab Shows Promising Phase 3 Results for Hidradenitis Suppurativa

Jun 21 2026seekingalpha